Recent developments in the medicinal chemistry of single boron atom-containing compounds.
10.1016/j.apsb.2021.01.010
- Author:
Shu SONG
1
;
Ping GAO
1
;
Lin SUN
1
;
Dongwei KANG
1
;
Jacob KONGSTED
2
;
Vasanthanathan POONGAVANAM
2
;
Peng ZHAN
1
;
Xinyong LIU
1
Author Information
1. Department of Medicinal Chemistry, Key Laboratory of Chemical Biology, Ministry of Education, School of Pharmaceutical Sciences, Shandong University, Ji'nan 250012, China.
2. Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Odense M. DK-5230, Denmark.
- Publication Type:Review
- Keywords:
ACTs, artemisinin combination therapies;
ADCs, Acinetobacter-derived cephalosporinases;
AML, acute myeloid leukemia;
AMT, aminopterin;
BLs, β-lactamases;
BNCT, boron neutron capture therapy;
BNNPs, boron nitride nanoparticles;
BNNTs, boron nitride nanotubes;
Boron-containing compounds;
CEs, carboxylesterases;
CIA, collagen-induced arthritis;
COVID-19, coronavirus disease 2019;
ClpP, casein protease P;
Covalent inhibitors;
GSH, glutathione;
HADC1, class I histone deacetylase;
HBV, hepatitis B virus;
HCV, hepatitis C virus;
HIV, human immunodeficiency virus;
LeuRS, leucyl-tRNA synthetase;
Linker components;
MBLs, metal β-lactamases;
MDR-TB, multidrug-resistant tuberculosis;
MERS, Middle East respiratory syndrome;
MIDA, N-methyliminodiacetic acid;
MM, multiple myeloma;
MTX, methotrexate;
Mcl-1, myeloid cell leukemia 1;
Mtb, Mycobacterium tuberculosis;
NA, neuraminidase;
NS5B, non-nucleoside polymerase;
OBORT, oxaborole tRNA capture;
OPs, organophosphate;
PBA, phenylboronic acid;
PDB, Protein Data Bank;
PPI, protein–protein interaction;
Prodrug;
QM, quinone methide;
RA, rheumatoid arthritis;
ROS, reactive oxygen species;
SARS-CoV-2, syndrome coronavirus 2;
SBLs, serine β-lactamases;
SERD, selective estrogen receptor downregulator;
SHA, salicyl hydroxamic acid;
SaClpP, Staphylococcus aureus caseinolytic protease P;
TB, tuberculosis;
TTR, transthyretin;
U4CR, Ugi 4-component reaction;
cUTI, complex urinary tract infection;
dCTPase, dCTPase pyrophosphatase
- From:
Acta Pharmaceutica Sinica B
2021;11(10):3035-3059
- CountryChina
- Language:English
-
Abstract:
Various boron-containing drugs have been approved for clinical use over the past two decades, and more are currently in clinical trials. The increasing interest in boron-containing compounds is due to their unique binding properties to biological targets; for example, boron substitution can be used to modulate biological activity, pharmacokinetic properties, and drug resistance. In this perspective, we aim to comprehensively review the current status of boron compounds in drug discovery, focusing especially on progress from 2015 to December 2020. We classify these compounds into groups showing anticancer, antibacterial, antiviral, antiparasitic and other activities, and discuss the biological targets associated with each activity, as well as potential future developments.
